First llama-derived antibody for COVID-19 headed to human trials

Although llamas may generally be known for their lush fur — and their cuteness — the pack animals have found a new place in the fight against COVID-19. This week, Belgium-based ExeVir Bio BV became the first company to embark on human trials of a single-dose llama-derived antibody COVID-19 drug.

The development of the drug was boosted by researchers at the Vlaams Institute for Biotechnology in Ghent (VIB) who found that antibodies in llama’s blood that could help neutralize COVID-19 effects. Looking at llama antibodies isn’t new in drug development, but is the first for COVID-19 prevention. ExeVir Bio is the first company to run with that research and crank out a potential treatment they’ve currently dubbed VHH72-Fc (XVR011). 

ExeVir’s drug will be observed in a phase 1b/2, randomized, double-blind, single-center, and placebo-controlled study to evaluate its pharmacokinetic activity and safety profile. The trial is aiming for conditional or emergency approval. The company also believes that it could be effective against the Delta variant, which is causing a surge in cases around the world.   

“XVR011 was recently demonstrated to neutralize the Delta variant, as well as all current COVID-19 variants of concern,” the company’s Chief Medical Officer, Dominique Tersago, said. Single-dose treatment for patients will first begin as an IV infusion, followed by a formulation for subcutaneous injection, according to Tersago. 

So far, four monoclonal antibody COVID-19 treatments have received emergency use authorizations from the FDA, with more to come. Each treatment offers different preventive measures. For example, Genentech’s Actemra is the only one out of the four intended for hospitalized adults and kids. Out of the four, GlaxoSmithKline and Vir’s Sotrovimab has the highest reduction rate (79%) of hospitalization or death.